| Assessment Status | Rapid Review Complete |
| HTA ID | 23049 |
| Drug | Chlormethine gel |
| Brand | Ledaga® |
| Indication | Chlormethine gel (Ledaga®) is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients. |
| Assessment Process | |
| Rapid review commissioned | 31/07/2023 |
| Rapid review completed | 20/09/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that chlormethine gel not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
